Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

Related Articles by Review for PubMed (Select 20348107)

1.

Interaction between DNA Polymerase lambda and anticancer nucleoside analogs.

Garcia-Diaz M, Murray MS, Kunkel TA, Chou KM.

J Biol Chem. 2010 May 28;285(22):16874-9. doi: 10.1074/jbc.M109.094391. Epub 2010 Mar 26.

2.

Structural basis for topoisomerase I inhibition by nucleoside analogs.

Gmeiner WH, Yu S, Pon RT, Pourquier P, Pommier Y.

Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):653-8. Review.

PMID:
14565246
3.

Cellular pharmacology of gemcitabine.

Mini E, Nobili S, Caciagli B, Landini I, Mazzei T.

Ann Oncol. 2006 May;17 Suppl 5:v7-12. Review.

4.

DNA polymerases as targets of anticancer nucleosides.

Miura S, Izuta S.

Curr Drug Targets. 2004 Feb;5(2):191-5. Review.

PMID:
15011952
5.

The steric hypothesis for DNA replication and fluorine hydrogen bonding revisited in light of structural data.

Egli M.

Acc Chem Res. 2012 Aug 21;45(8):1237-46. doi: 10.1021/ar200303k. Epub 2012 Apr 23. Review.

6.

New nucleoside analogs in the treatment of solid tumors.

Szafraniec SI, Stachnik KJ, Skierski JS.

Acta Pol Pharm. 2004 Jul-Aug;61(4):297-305. Review.

7.

Ubiquitylation of DNA polymerase λ.

Markkanen E, van Loon B, Ferrari E, Hübscher U.

FEBS Lett. 2011 Sep 16;585(18):2826-30. doi: 10.1016/j.febslet.2011.03.069. Epub 2011 Apr 8. Review.

8.

Preclinical characteristics of gemcitabine.

Plunkett W, Huang P, Gandhi V.

Anticancer Drugs. 1995 Dec;6 Suppl 6:7-13. Review.

PMID:
8718419
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk